BLA
TRIB

Balter Liquid Alternatives’s Trinity Biotech TRIB Stock Holding History

Balter Liquid Alternatives’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-21,762
Closed -$753K – 80
2016
Q4 		$753K Sell
21,762
-10,495
-33% -$361K 1.71% 20
2016
Q3 		$2.21M Hold
32,257
– – 5.56% 4
2016
Q2 		$1.83M Hold
32,257
– – 4.29% 10
2016
Q1 		$1.88M Sell
32,257
-2,428
-7% -$129K 4.33% 8
2015
Q4 		$2.04M Buy
+34,685
New +$2.05M 7.32% 4

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

Balter Liquid Alternatives's TRIB Position: Q1 2017 in Review

Balter Liquid Alternatives sold out of Trinity Biotech (TRIB) in Q1 2017, closing a stake of 21,762 shares — an estimated $753K sold.

Balter Liquid Alternatives first reported a position in TRIB in Q4 2015 and held it in 5 quarters. The position peaked at $2.21M in Q3 2016. 67 funds tracked by Wall St. Rank hold TRIB as of Q1 2017.

  • Balter Liquid Alternatives reported no remaining Trinity Biotech position as of Q1 2017 after selling out during the quarter.
  • Balter Liquid Alternatives sold 21,762 Trinity Biotech shares in Q1 2017, an estimated $753K.
  • Balter Liquid Alternatives first reported a position in Trinity Biotech in Q4 2015 and held it in 5 quarters.
  • Balter Liquid Alternatives's Trinity Biotech position peaked at $2.21M in Q3 2016.
  • 67 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2017.

Based on Balter Liquid Alternatives's 13F filing for Q1 2017, filed 12 May 2017.